Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca AB
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Efficacy and safety of AZD9056 200 mg once daily versus placebo in adult patients with active Crohn’s disease – A randomized, double-blind, four week, parallel-group, multicentre, phase II study
The primary objective of this study is to study the efficacy of a daily dose of 200 mg AZD9056 in patients with active CD affecting ileum and/or colon by assessment of the change in CDAI from baseline...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
Study of MEDI4736 monotherapy and MEDI4736 in combination with Tremelimumab versus Standard of Care Therapy in patients with SCCHN
- To assess the efficacy of MEDI4736 + tremelimumab combination therapy versus SoC in terms of OS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 24-week, Multi-centre, International, Double-blind, Randomized, Parallel-group, Placebo-controlled, Phase III Study with a 78-week Extension Period to Evaluate the Effect of Dapagliflozin in Combination with Metformin on Body Weight in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin Alone
To evaluate the effect of dapagliflozin 10 mg daily in combination with metformin compared to placebo in combination with metformin on total body weight after 24 weeks of oral administration of double...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A randomised Phase II Study comparing anastrozole and fulvestrant to an-astrozole for adjuvant treatment of postmenopausal patients with early breast cancer and disseminated tumour cells in bone marrow - ABCSG 21
The primary objective of this study is to compare the frequency of events (i.e., presence of DTC in BM, clinical recurrence and/or death) in patients treated with anastrozole-fulvestrant combination a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 16-week, Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Safety and Efficacy of Dapagliflozin 2.5 mg BID, 5 mg BID and 10 mg QD Versus Placebo in Patients with Type 2 Diabetes Who Are Inadequately Controlled on Metformin-IR Monotherapy
To compare the change from baseline in HbA1c achieved with each of the 2 BID doses of dapagliflozin (2.5 mg BID and 5 mg BID) co-administered with metformin versus placebo co-administered with metform...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 24-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy when Added to the Therapy of Patients with Type 2 Diabetes Poorly Controlled on Sulphonylurea Alone Estudio aleatorizado de 24 semanas, doble ciego, de grupos paralelos, controlado con placebo, multicéntrico, para evaluar la eficacia, seguridad y tolerabilidad del tratamiento con Tesaglitazar cuando se añade al tratamiento de pacientes con Diabetes tipo 2 mal controlados con Sulfonilurea en monoterapia. GALLANT 7
To assess the efficacy of tesaglitazar (0.5 and 1 mg) as compared to placebo given as add-on therapy to sulphonylurea for 24 weeks in improving glycaemic control in patients with type 2 diabetes as de...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A study of AZD8931 and anastrozole for hormone receptor positive advanced breast cancer (MINT)
To compare Progression Free Survival (PFS) in patients treated with AZD8931 given in combination with anastrozole versus anastrozole alone.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Double-blind, Randomised, 4-arm Parallel Group, Multicentre, 8-week, Phase III Study to Assess the Antihypertensive Efficacy and Safety of the Combination of Candesartan Cilexetil 32 mg and Hydrochlorothiazide 25 mg in Comparison with Candesartan Cilexetil 32 mg, Hydrochlorothiazide 25 mg and Placebo in Hypertensive Adults
1.To compare sitting DBP lowering effect of candesartan cilexetil (candesartan)/hydrochlorothiazide (HCT) 32/25 mg with that of candesartan 32 mg. 2. To compare sitting Systolic Blood Pressure (SBP) l...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A randomized, double-blind, double-dummy, two-way cross-over study evaluating systemic bioavailability and airway clearance of Symbicort® Turbuhaler® 320/9μg/inhalation versus Seretide™ Diskus ™50/500μg/inhalation after single inhalations in patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers
The primary objective is to evaluate airway tissue availability of budesonide via Symbicort Turbuhaler and fluticasone via Seretide Diskus in severe COPD patients and healthy volunteers, using area un...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A phase II, open label, multiarm study to assess the efficay of new drugs in patients with Small Cell Lung Cancer whose cancer worsened during or after 90 days of platinum based chemotherapy Ensayo fase II, abierto, multi-brazo para determinar la eficacia de nuevos medicamentos en pacientes con cáncer de pulmón de células pequeñas cuyo cáncer empeorado durante o después de 90 días de quimioterapia basada en platino
To assess the preliminary efficacy of each treatment arm in terms of Overall Response Rate. ORR will be evaluated using Investigator assessments according to RECIST 1.1 Evaluar la eficacia preli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
7
8
9
10
11
12
13
14
15
16
Suivant